Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC).
dc.contributor.author | Walsh, Lorraine | |
dc.contributor.author | Gillham, Charles | |
dc.contributor.author | Dunne, Mary | |
dc.contributor.author | Fraser, Ian | |
dc.contributor.author | Hollywood, Donal | |
dc.contributor.author | Armstrong, John | |
dc.contributor.author | Thirion, Pierre | |
dc.date.accessioned | 2011-05-25T13:29:52Z | |
dc.date.available | 2011-05-25T13:29:52Z | |
dc.date.issued | 2011-01 | |
dc.identifier.citation | Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). 2011, 98 (1):38-41 Radiother Oncol | en |
dc.identifier.issn | 1879-0887 | |
dc.identifier.pmid | 21159400 | |
dc.identifier.doi | 10.1016/j.radonc.2010.11.009 | |
dc.identifier.uri | http://hdl.handle.net/10147/132015 | |
dc.description | We retrospectively reviewed acute toxicity with cetuximab and radiotherapy, comparing it with a matched cisplatin group. The cetuximab group experienced significantly more toxicity--grade ≥3 oral mucositis (p=0.014), skin dermatitis (p=0.0004), ≥10% weight loss (p=0.03), and enteral feeding requirement (p=0.05). This finding of enhanced toxicity is similar to recent publications. | en |
dc.description.abstract | We retrospectively reviewed acute toxicity with cetuximab and radiotherapy, comparing it with a matched cisplatin group. The cetuximab group experienced significantly more toxicity--grade ≥3 oral mucositis (p=0.014), skin dermatitis (p=0.0004), ≥10% weight loss (p=0.03), and enteral feeding requirement (p=0.05). This finding of enhanced toxicity is similar to recent publications. | |
dc.language.iso | en | en |
dc.publisher | Elsevier | en |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Antibodies, Monoclonal | |
dc.subject.mesh | Antineoplastic Agents | |
dc.subject.mesh | Carcinoma | |
dc.subject.mesh | Cisplatin | |
dc.subject.mesh | Combined Modality Therapy | |
dc.subject.mesh | Female | |
dc.subject.mesh | Head and Neck Neoplasms | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Neoplasms, Squamous Cell | |
dc.subject.mesh | Patient Compliance | |
dc.subject.mesh | Radiotherapy Dosage | |
dc.subject.mesh | Retrospective Studies | |
dc.title | Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). | en |
dc.type | Article | en |
dc.contributor.department | Department of Radiation Oncology, St. Luke's Hospital, Dublin, Ireland. | en |
dc.identifier.journal | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | en |
dc.description.province | Leinster | |
html.description.abstract | We retrospectively reviewed acute toxicity with cetuximab and radiotherapy, comparing it with a matched cisplatin group. The cetuximab group experienced significantly more toxicity--grade ≥3 oral mucositis (p=0.014), skin dermatitis (p=0.0004), ≥10% weight loss (p=0.03), and enteral feeding requirement (p=0.05). This finding of enhanced toxicity is similar to recent publications. |